
Speaking to reporters in Brussels after the European Union (EU) leaders' summit, Merz shared his thoughts on reducing the amount that public insurance funds pay for advanced medicines. He said that was a decision within national authority.
Prime Minister Merz's government is pushing to improve the public health insurance system to fill a spending gap expected to exceed 40 billion euros by the end of this decade. This healthcare plan, which could be approved by the German Parliament next week, includes measures to reduce pharmaceutical spending by increasing discounts.
The US has criticized these efforts to cut drug prices. Germany is crucial for American drug manufacturers because it is not only the largest pharmaceutical market in Europe but also has a history of paying some of the highest prices on the continent.
This country also allows for the rapid launch of expensive new drugs without forcing pharmaceutical companies to wait.
Source: https://quangngaitv.vn/duc-phan-doi-cuoc-dieu-tra-duoc-pham-cua-my-6521718.html








